Evidence map›Paper›PMID 41548132›Full record

ArticleACS applied materials & interfaces2026

PD-L1 Blockade with Biodegradable Envafolimab-Loaded Microspheres Synergizes with Transarterial Chemoembolization to Overcome Myeloid-Derived Suppressor Cell-Driven Immune Escape in Hepatocellular Carcinoma.

Hanyuan Liu, Jinxin Huang, Zixuan Wang, Nuofan Wang, Xiaopei Hao, Yue Chai, Na Yu, Hengsong Cao, Yanshu He, Shipeng Dai and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS applied materials & interfaces, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Hanyuan LiuKey Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Jinxin HuangState Key Laboratory of Digital Medical Engineering, Jiangsu Key Laboratory for Biomaterials and Devices, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210029, China.
Zixuan WangDepartment of Radiation Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Nanjing 210000, China.
Nuofan WangDepartment of Hepato-Pancreatico-Biliary Surgery, Zhongda Hospital Southeast University, Nanjing 210009, China.
Xiaopei HaoDepartment of Hepatobiliopancreatic Surgery, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou 450000, China.
Yue ChaiKey Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Na YuDepartment of Pharmaceutical Preparation, General Hospital of Ningxia Medical University, Yinchuan 750004, China.
Hengsong CaoKey Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Yanshu HeKey Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Shipeng DaiKey Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Jintao XuSchool of Chinese Medicine, Chinese University of Hong Kong, Hong Kong 518172, China.
Zongkang ZhangSchool of Chinese Medicine, Chinese University of Hong Kong, Hong Kong 518172, China.
Jie KongDepartment of Intervention, Nanjing First Hospital, Nanjing Medical University, Nanjing 210000, China.
Fei XiongState Key Laboratory of Digital Medical Engineering, Jiangsu Key Laboratory for Biomaterials and Devices, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210029, China.ORCID 0000-0002-3680-4292
Weiwei TangKey Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.ORCID 0000-0002-8516-819X
Jinhua SongKey Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, NHC Key Laboratory of Living Donor Liver Transplantation, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transarterial chemoembolization (TACE) remains a cornerstone locoregional therapy for hepatocellular carcinoma (HCC), yet post-TACE tumor recurrence remains a critical challenge. Our single-cell RNA analysis reveals that tumor recurrence is mechanistically linked to TACE-induced expansion of PD-L1

Indexed as

Antibodies, Monoclonal, HumanizedB7-H1 AntigenCarcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsMicrospheresMyeloid-Derived Suppressor CellsAnimalsCell Line, TumorHumansMiceMice, Inbred BALB CTumor EscapeTumor MicroenvironmentAntibodies, Monoclonal, HumanizedB7-H1 Antigenhepatocellular carcinomaKN035microspheresmyeloid-derived suppressor cellstransarterial chemoembolization

Identifiers

PMID41548132
PMCPMC12862755

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.